Arcellx (ACLX) Stock Price

Arcellx Price

NASDAQ·CLOSED
115.07
​
Market closed

Over the last 3 years Arcellx grew revenue by 7.6% annually, reaching 22.29 M USD. For Arcellx, the net margin of -1,027.3% is up versus -1,053.4% a few years ago. The consensus 12-month price target for Arcellx is 114.24 USD, about 0.7% below where the stock trades today. Of 26 analysts, 23 rate the stock a buy — an overall Buy consensus.

Arcellx stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx business model & stock analysis

Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages.

Frequently asked questions about Arcellx

Analysts currently set an average price target of 114.60 USD for the Arcellx stock (median: 114.24 USD), implying -0.4 % versus the latest price. The consensus is based on 26 analyst ratings.

26 analysts currently rate the Arcellx stock: 23 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Arcellx to generate revenue of 73.34 M USD and earnings per share of -3.77 USD.

Converted at the current exchange rate, the Arcellx share trades at 104.80 EUR (115.07 USD).

The Arcellx share (ACLX) is listed on 1 stock exchanges, including: NASDAQ (ACLX).

The expected revenue of Arcellx is 73.34 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Arcellx is -212.17 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Arcellx is currently -30.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Arcellx stock.

The price-to-sales ratio (P/S) of Arcellx is currently 88.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Arcellx stock.

The Eulerpool Quality Score for Arcellx is 5/10.

The ISIN of Arcellx is US03940C1009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Arcellx is ACLX. The ticker symbol is used to trade Arcellx shares on the stock exchange.

Fair ValueTerminal
94.36 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
106,631.58 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website arcellx.com
Currency
USD
Initial public offering
Feb 4, 2022
ISIN
US03940C1009
Cusip
03940C100
Market capitalization
6.65 B USDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-30.54
P/Ee 2027
-65.66
P/Ee 2028
292.50
P/Ee 2029
29.71
P/Ee 2030
15.50
P/Se
88.34
EV/EBIT
—
P/B Ratio
16.54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-55.85 %
Last updated Nov 20, 2026, 3:41 AM

Arcellx Peer Group

Arcellx Ticker

NASDAQ · ACLX

Arcellx FIGI

ACLX:US · BBG00QHJM4S9ACLX:UA · BBG014L7WVJ7ACLX:UC · BBG014L7WVK5ACLX:UN · BBG014L7WVM3ACLX:UP · BBG014L7WVN2ACLX:UB · BBG014L7WVQ9ACLX:UM · BBG014L7WVS7ACLX:UX · BBG014L7WVT6ACLX:UD · BBG014L7WVZ9ACLX:UW · BBG014L7WW14ACLX:UF · BBG014L7WW23ACLX:VY · BBG014L7WW32

All fundamentals and in-depth analysis of Arcellx

Our stock analysis for Arcellx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arcellx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.